DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06701305

CompletedPhase 1

A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)

A Single and Multiple-Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Efinopegdutide (MK-6024) in Otherwise Healthy Obese Participants and the Effect of Multiple Doses of Efinopegdutide on the Pharmacokinetics of Acetaminophen

Asset

Efinopegdutide

Subcutaneous · GLP-1 / glucagon dual

Listed sites

1

Recruiting sites

—

Enrollment

48

actual

Study population

Healthy volunteers, Obesity / overweight

Key I/E criterion

•BMI 29-38

Primary endpoints

•Treatment-emergent AEs (any)•Discontinuation due to AE•Part 1

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06701305
Org study ID6024-015
Secondary IDMK-6024-015MSD

Timeline

Milestones

Study start2024-06-13actual
Study first posted2024-11-22actual
Primary completion2025-02-18actual
Study completion2025-02-18actual
Last update posted2025-02-26actual

Assets

Investigational agents

Efinopegdutide

Study populations

Who this study enrolls

Healthy volunteersObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

•Is in good health
•Has body mass index (BMI) between 29 kg/m^2 and 38 kg/m^2

Exclusion criteria

The main exclusion criteria include but are not limited to the following:

•History of clinically significant endocrine, gastrointestinal (GI), cardiovascular (CV), hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
•History of cancer (malignancy)
•Positive test(s) for Hepatitis B surface antigen (HBsAg), hepatitis C antibodies, or Human immunodeficiency virus (HIV)

Endpoints (21)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

21 endpoints
Primary/protocol endpoint

Part 1: Number of Participants Who Experience an Adverse Event (AE)

Time frame:Up to approximately 35 days

Treatment-emergent AEs (any)

event count, event

Primary/protocol endpoint

Part 1: Number of Participants Who Discontinue Study Treatment Due to an AE

Time frame:Up to approximately 35 days

Discontinuation due to AE

event count, event

Primary/protocol endpoint

Part 1: Maximum Plasma Concentration (Cmax) of Efinopegdutide

Time frame:Pre-dose and at designated time points up to 35 days post dose

Cmax

concentration, descriptive

Primary/protocol endpoint

Part 1: Time to Maximum Plasma Concentration (Tmax) of Efinopegdutide

Time frame:Pre-dose and at designated time points up to 35 days post dose

Tmax

descriptive

Primary/protocol endpoint

Part 1: Area Under the Concentration-Time Curve from Time 0 to Last Measurable Concentration (AUC0-last) of Efinopegdutide

Time frame:Pre-dose and at designated time points up to 35 days post dose

concentration, descriptive

Primary/protocol endpoint

Part 1: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Efinopegdutide

Time frame:Pre-dose and at designated time points up to 35 days post dose

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

Part 1: Apparent Terminal Half-life (t1/2) of Efinopegdutide

Time frame:Pre-dose and at designated time points up to 35 days post dose

Half-life

descriptive

Primary/protocol endpoint

Part 1: Apparent Clearance (CL/F) of Efinopegdutide

Time frame:Pre-dose and at designated time points up to 35 days post dose

descriptive

Primary/protocol endpoint

Part 1: Apparent volume of distribution during terminal phase (Vz/F) of Efinopegdutide

Time frame:Pre-dose and at designated time points up to 35 days post dose

descriptive

Primary/protocol endpoint

Part 2: Number of Participants Who Experience an Adverse Event (AE)

Time frame:Up to approximately 184 days

Treatment-emergent AEs (any)

event count, event

Primary/protocol endpoint

Part 2: Number of Participants Who Discontinue Study Treatment Due to an AE

Time frame:Up to approximately 184 days

Discontinuation due to AE

event count, event

Primary/protocol endpoint

Part 2: Cmax of Efinopegdutide

Time frame:At designated time points up to approximately 184 days

Cmax

concentration, descriptive

Primary/protocol endpoint

Part 2: Tmax of Efinopegdutide

Time frame:At designated time points up to approximately 184 days

Tmax

descriptive

Primary/protocol endpoint

Part 2: Area Under the Concentration-Time Curve from Time 0 to the End of the Dosing Interval (AUC0-tau) of Efinopegdutide

Time frame:At designated time points up to approximately 184 days

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

Part 2: t1/2 of Efinopegdutide

Time frame:At designated time points up to approximately 184 days

Half-life

descriptive

Primary/protocol endpoint

Part 2: Vz/F of Efinopegdutide

Time frame:At designated time points up to approximately 184 days

descriptive

Primary/protocol endpoint

Part 2: Concentration Immediately Before the Next Dose is Administered (Ctrough) of Efinopegdutide

Time frame:At designated time points up to approximately 184 days

Plasma concentration (steady state)

concentration, descriptive

Secondary/protocol endpoint

Part 2: AUC0-Inf of Acetaminophen

Time frame:At designated time points up to approximately 184 days

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

Part 2: Cmax of Acetaminophen

Time frame:At designated time points up to approximately 184 days

Cmax

concentration, descriptive

Secondary/protocol endpoint

Part 2: Tmax of Acetaminophen

Time frame:At designated time points up to approximately 184 days

Tmax

descriptive

Secondary/protocol endpoint

Part 2: t1/2 of Acetaminophen

Time frame:At designated time points up to approximately 184 days

Half-life

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.